<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492710</url>
  </required_header>
  <id_info>
    <org_study_id>GC5101F</org_study_id>
    <nct_id>NCT03492710</nct_id>
  </id_info>
  <brief_title>Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency</brief_title>
  <official_title>Phase III Study of Immune Globulin Intravenous (Human) IGIV-SN in Pediatric Subjects With Primary Humoral Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, efficacy, and pharmacokinetics of IGIV-SN in pediatric subjects with
      primary immunodeficiency humoral diseases (PHID)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Incidence of Acute SBIs (Serious Bacterial Infections)</measure>
    <time_frame>13 months (12 months of treatment + 1 month of Follow-Up)</time_frame>
    <description>The incidence of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Overall Incidence of AEs that occur during 72 hours of following an infusion of test drug</measure>
    <time_frame>13 months (12 months of treatment + 1 month of Follow-Up)</time_frame>
    <description>The overall incidence of adverse events (AEs) that occur during or within 1 hours, 24 hours, and 72 hours following an infusion of test product, regardless of whether or not the AE is determined to be product related</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Incidence of Infections other than acute serious bacterial infections</measure>
    <time_frame>13 months (12 months of treatment + 1 month of Follow-Up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: The frequency of all AEs that occuring during the study</measure>
    <time_frame>13 months (12 months of treatment + 1 month of Follow-Up)</time_frame>
    <description>(regardless of the casual relationship)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PK Endpoint (1)</measure>
    <time_frame>13 months (12 months of treatment + 1 month of Follow-Up)</time_frame>
    <description>Plasma Concentration-Time Curve (PK Parameters of Total IgG)</description>
  </other_outcome>
  <other_outcome>
    <measure>PK Endpoint (2)</measure>
    <time_frame>13 months (12 months of treatment + 1 month of Follow-Up)</time_frame>
    <description>Area Under the Curve (PK Parameters of Total IgG)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>IGIV-SN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunoglobulin</intervention_name>
    <description>Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more</description>
    <arm_group_label>IGIV-SN</arm_group_label>
    <other_name>IGIV-SN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric subjects with a confirmed clinical diagnosis of a Primary Humoral
             Immunodeficiency Disease as defined by IUIS (International Union of Immunological
             Societies) and require treatment with IGIV. Documented agammaglobulinemia or
             hypogammaglobulinemia

          -  Subject is willing to comply with all requirements of protocol

          -  Authorization to access personal health information

        Exclusion Criteria:

          -  Subject has secondary immunodeficiency

          -  Subject has a history of repeated reactions or hypersensitivity to IGIV or other
             injectable forms of IgG

          -  Subject has significant protein loss from enteropathy, nephrotic syndrome or
             lymphangiectasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>203 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaim Roifman</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JI Lee</last_name>
    <phone>+82-32-260-1968</phone>
    <email>jylee817@greencross.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 8, 2018</last_update_submitted>
  <last_update_submitted_qc>April 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

